Recent Updates
Recently added Catalysts
ERAS Positive Sentiment Score: 75/100

Erasca to Present at the Bank of America Health Care Conference

Key Takeaway: Erasca, Inc. announced its participation in the Bank of America Health Care Conference scheduled for May 15, 2024, in Las Vegas, Nevada. The clinical-stage precision oncology company focuses on therapies for RAS/MAPK pathway-driven cancers. Management will present at the conference and participate in one-on-one investor meetings, enhancing their visibility and engagement within the healthcare sector. The event will be available for streaming online, indicating transparency in their communications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Erasca is actively engaging with investors, showcasing confidence in its strategies.
  • Participation in a significant healthcare conference indicates strong visibility and potential partnerships.
  • The company has a strong pipeline focused on RAS/MAPK pathway-driven cancers, suggesting innovative prospects in oncology.

Full Press Release Details

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
LifeSci Advisors, LLC
Source: Erasca, Inc.

Frequently Asked Questions

What is Erasca, Inc. focused on?

Erasca, Inc. focuses on therapies for RAS/MAPK pathway-driven cancers.

When will Erasca present at the Bank of America Conference?

Erasca will present on May 15, 2024, at 4:20 pm PT.

Where can I watch the Erasca conference webcast?

The webcast will be available at Erasca.com/events.

What is Erasca's mission?

Erasca's mission is to erase cancer through innovative therapies.

Who co-founded Erasca, Inc.?

Erasca was co-founded by pioneers in precision oncology and RAS targeting.

Last updated: May 7, 2024